Alcon (ALC) Q3 2025 earnings summary

Executive summary

• Q3 2025 net sales reached $2.6 billion, up 6% year-over-year, with strong momentum in Equipment and Ocular Health, and successful launches of Unity VCS and PanOptix Pro.

• Contact lens business outpaced the market, especially in toric modalities, and Ocular Health saw high single-digit growth, led by Systane and the launch of Tryptyr.

• Core operating margin for Q3 2025 was 20.2%, down 40 bps year-over-year; core diluted EPS was $0.79.

• Free cash flow for the first nine months was $1.2 billion, with cash from operations at $1.6 billion.

• Net income for Q3 was $237 million, down 10% year-over-year, mainly due to higher tax expense.

Financial highlights

• Q3 sales reached $2.6 billion, up 6% year-over-year; Surgical revenue was $1.4 billion (+6%), Vision Care $1.2 billion (+7%).

• Core gross margin was 62.9%, down 50 bps year-over-year; operating margin was 12.8%, down 80 bps.

• Core diluted EPS was $0.79, down 4% year-over-year; Q3 EPS was $0.48, down from $0.53.

• Free cash flow for the first nine months was $1.2 billion; capex was $374 million.

• 9M25 net sales were $7.6 billion, up 4% year-over-year.

Outlook and guidance

• Full-year 2025 sales guidance reaffirmed at $10.3–10.4 billion, with 4–5% constant currency growth.

• Core operating margin outlook is 19.5–20.5%; core diluted EPS guidance is $3.05–3.15, up 0–2%.

• Management expects to offset the estimated $100 million gross impact of new tariffs in 2025 through FX and operational actions.

• 2026 expected to see continued acceleration from new launches, but incremental tariff impact of $50–100 million and 40 bps margin pressure from Aurion and clinical trial investments.